Revenue segments as reported by the company.

Protein Sciences

Diagnostics and Genomics

lntersegment

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bio-Techne

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics & Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded in 1976 and is headquartered in Minneapolis, MN.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Bio-Techne Corp reports steady Q3 revenue growth amidst China challenges

Bio-Techne Corp reported steady Q3 revenue growth despite challenges in China and temporary headwinds. The company is focused on driving growth in strategic platforms and expanding key franchises. Succession planning and margin improvement are key areas of focus for future growth.

Bio-Techne reports strong Q2 earnings, eyes growth in diagnostics

Bio-Techne's Q2 2023 earnings call highlighted solid performance, strategic strengths in key segments, challenges in ordering patterns, and growth opportunities in diagnostics and research.
The company's focus on innovation, cost management, and strategic investments positions it well for future growth and reaching ambitious revenue targets by FY 2026.
Despite short-term challenges in certain markets, Bio-Techne remains optimistic about its long-term growth prospects and transparent communication with investors.
With a strong financial performance, expanding product portfolio, and a focus on high-growth areas, Bio-Techne is poised for sustained success and market leadership.

Bio-Techne reports solid Q3 performance, eyes growth in key segments

Bio-Techne's Q3 performance showcased strengths in key segments like ExoDx Prostate test demand and GMP proteins, despite challenges in certain markets and OEM destocking dynamics. The company's strategic focus on expanding the Wilson Wolf franchise and driving growth in ACD and key segments like cell and gene therapy position it well for future success. Addressing challenges and capitalizing on growth opportunities will be pivotal for Bio-Techne's continued expansion and market leadership.

Bio-Techne (TECH) excels in Q4, eyes growth amid challenges

Bio-Techne (TECH) reports strong revenue growth and promising future prospects.
Strategic focus on key segments like cell and gene therapy and spatial biology.
Challenges in macroenvironment and funding uncertainties require cautious navigation.
Active M&A strategy and investments to drive growth and market dominance.

Bio-Techne reports steady Q1 growth amid industry challenges

Bio-Techne's Q1 performance showed resilience amidst industry challenges, with a focus on key growth areas and regions. While facing headwinds, the company remains cautiously optimistic about future prospects, emphasizing long-term growth opportunities and productivity measures.

Bio-Techne reports Q2 revenue growth amidst China challenges and opportunities

Bio-Techne's Q2 performance reflects revenue growth and operational efficiency, despite challenges.
Strengths lie in core businesses, Diagnostics and Genomics growth, and record consumables usage in China.
Challenges include market declines, funding constraints, and headwinds in biopharma and academic markets.
Opportunities exist in market normalization, China growth, new product releases, and M&A strategies.

Bio-Techne surpasses Q3 expectations, eyes growth in emerging markets

Bio-Techne's Q3 showcased strong financial performance, with revenue growth and margin expansion across key segments, setting the stage for continued success.
The company's focus on innovation, awards recognition, and strategic market positioning in high-growth areas like cell and gene therapy underpin its competitive strength.
While facing challenges in certain regions and production constraints, Bio-Techne's proactive approach to scaling up manufacturing and diversifying markets positions it well for future growth.
With a clear emphasis on operational efficiency, market expansion, and strategic investments, Bio-Techne is poised for sustained success and value creation for stakeholders.

Bio-Techne reports solid Q4 performance and eyes market recovery

Bio-Techne's Q4 2024 performance reflects resilience and potential for accelerated growth as markets recover in fiscal year 2025.
Strategic leadership additions, productivity initiatives, and market recovery expectations position the company for future success.
Challenges such as capacity constraints and funding environments require strategic management for sustained growth.
Opportunities lie in market recovery, margin improvement, and growth prospects across different segments for Bio-Techne in the coming year.

Bio-Techne reports solid Q1 earnings, eyes growth in biotech markets

Bio-Techne (TECH) delivered solid Q1 2025 results with organic revenue growth, strong segment performances, and a focus on sustainability and strategic partnerships.
While facing challenges in certain markets, the company's emphasis on cost containment and productivity optimization bodes well for future profitability and resilience.
With a positive outlook for growth and opportunities in key segments, Bio-Techne is poised for continued success and market leadership in the biotech industry.
Investors can be optimistic about Bio-Techne's performance, strategic initiatives, and growth prospects, supported by a strong financial foundation and market positioning.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. It operates through the Protein Sciences, and Diagnostics and Genomics segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Genomics segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN.

MINNEAPOLIS , July 31, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is pleased to announce the launch of the Leo™ System. This next-generation Simple Western™ instrument offers higher throughput, flexibility, and efficiency over the current Jess™ and Abby™ Simple Western Systems.

BIO-TECHNE ANNOUNCES NEXT-GENERATION HIGH THROUGHPUT SIMPLE WESTERN SYSTEM

MINNEAPOLIS , July 29, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced its participation in Spear Bio's $45 million Series A funding round. Spear Bio will use the proceeds from this funding round to further accelerate product development and scale its in-house manufacturing capacity.

BIO-TECHNE ANNOUNCES STRATEGIC INVESTMENT IN SPEAR BIO

MINNEAPOLIS , July 15, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, August 7, 2024, at 8:00 a.m. CDT to review fourth quarter and fiscal 2024 financial results.

BIO-TECHNE TO HOST CONFERENCE CALL ON AUGUST 7, 2024, TO ANNOUNCE FOURTH QUARTER AND FISCAL 2024 FINANCIAL RESULTS

Genmab - ADR

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Genmab A/S Sponsored ADR (GMAB) or Techne (TECH). But which of these two stocks presents investors with the better value opportunity right now?

GMAB or TECH: Which Is the Better Value Stock Right Now?

Alnylam Pharmaceuticals

Amgen

Exelixis

Gilead Sciences

Harmony Biosciences Holdings

Incyte

Intuitively, the case for biotechnology-related investments comes across rather obviously: the concept of healthcare should be a permanent one. And because of this permanence, the expected market value of the ecosystem should be massive.

7 Cheap Biotech Stocks With Major Upside Potential

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Genmab A/S Sponsored ADR (GMAB) and Techne (TECH). But which of these two stocks presents investors with the better value opportunity right now?

GMAB vs. TECH: Which Stock Is the Better Value Option?

MINNEAPOLIS , May 31, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer will present at the following investor conferences: William Blair 44th Annual Growth Conference June 4, 2024 9:20 AM CDT Jefferies Global Healthcare Conference June 6, 2024 9:30 AM EDT Goldman Sachs 45th Annual Global Healthcare Conference June 11, 2024 9:20 AM EDT A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. About Bio-Techne  Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities.

BIO-TECHNE TO PRESENT AT UPCOMING INVESTOR CONFERENCES

MINNEAPOLIS, May 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) will showcase multiple applications of its recently launched MauriceFlex™ System at the 72nd ASMS Conference on Mass Spectrometry and Allied Topics, taking place June 2 nd-6th in Anaheim, California. The MauriceFlex system is Bio-Techne's latest imaged capillary isoelectric focusing (icIEF) solution, which enables icIEF-based fractionation in addition to routine icIEF and capillary electrophoresis-sodium dodecyl sulfate (CE-SDS) assays.

BIO-TECHNE TO HIGHLIGHT MULTIPLE APPLICATIONS OF THE MauriceFlex™ SYSTEM AT THE ANNUAL ASMS CONFERENCE

ST. PAUL, Minn. , May 29, 2024 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced the launch of the G-Rex® Grant Program, a $20 million initiative to propel the advancement of cell and gene therapies (CGT).

ScaleReady Announces $20 Million G-Rex® Grant Program for the Advancement of Cell and Gene Therapy (CGT) Development and Manufacturing

MINNEAPOLIS , May 23, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer will present at the 2024 Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024, at 8:40 a.m. CDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

BIO-TECHNE TO PRESENT AT THE 2024 LEERINK PARTNERS HEALTHCARE CROSSROADS CONFERENCE

MINNEAPOLIS, May 22, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced continued technical and clinical collaboration following release of Regulus' positive topline results from the second cohort of patients in its Phase 1b MAD (multiple ascending dose) study of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). The two companies began the collaboration in 2020 to support Regulus' biomarker analysis for the clinical development of anti-miR-17 therapies for ADPKD treatment.

BIO-TECHNE HIGHLIGHTS RECENTLY ANNOUNCED TOP-LINE BIOMARKER DATA FROM PARTNER, REGULUS THERAPEUTICS, USING THE COMPANY'S PROPRIETARY TECHNOLOGY

LOS ANGELES--(BUSINESS WIRE)-- #Biotech--Molecular Instruments announced that UK Patents Court orders Advanced Cell Diagnostics to make £1.35 million costs payment to Molecular Instruments.

Court Revokes Two Advanced Cell Diagnostics Patents, Dismisses Infringement Claims Against Molecular Instruments and Orders Advanced Cell Diagnostics to Make Payment of £1.35 Million to Molecular Instruments

AstraZeneca

Novo Nordisk

Regeneron Pharmaceuticals

United Therapeutics

Fundamentally, one of the biggest advantages of biotech stocks to buy centers on the underlying prioritization. While the media focuses on attaining wealth, that doesn't mean much if you don't have health.

7 Biotech Stocks That Could Breathe New Life Into Your Portfolio

Amcor Plc

Aptiv Holdings Ltd

Garmin

Howmet Aerospace

The S&P 500 is up for the fourth consecutive session. While many stocks have powered the ETF, we have highlighted five that have led the way higher.

5 Stocks at the Forefront of S&P 500 ETF's Latest Rally

MINNEAPOLIS , May 8, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the BofA Securities Health Care Conference on Tuesday, May 14, 2024, at 2:20 p.m. PDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

BIO-TECHNE TO PRESENT AT THE BofA SECURITIES HEALTH CARE CONFERENCE 2024

MINNEAPOLIS , May 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its portfolio of cell and gene therapy workflow solutions at the upcoming annual meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 7-11, 2024, in Baltimore, Maryland. Bio-Techne's booth (#1627) will feature our market-leading portfolio of high-quality life science research use only (RUO) and Good Manufacturing Practice (GMP) reagents, immunoassays, automated proteomic analytical instruments, and multi-omics solutions for accelerating cell and gene therapy development and manufacturing.

BIO-TECHNE TO PRESENT AT THE 27TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT)

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and Techne (TECH). But which of these two stocks offers value investors a better bang for their buck right now?

HRMY or TECH: Which Is the Better Value Stock Right Now?

The headline numbers for Techne (TECH) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Techne (TECH) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Techne (TECH) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.53 per share a year ago.

Techne (TECH) Q3 Earnings and Revenues Beat Estimates

Bio-Techne on Wednesday beat third-quarter profit and revenue estimates, helped by better-than-expected demand for its cell and gene therapy products and testing and diagnostic devices.

Bio-Techne beats third-quarter estimates on improving demand for biotech products

MINNEAPOLIS , May 1, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2024. Third Quarter FY2024 Highlights Third quarter organic revenue increased by 2% (3% reported) to $303.4 million.

BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2024 RESULTS

MINNEAPOLIS , April 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the appointment of Dr. Judith Klimovsky to serve as an independent director on the Company's Board of Directors, April 24, 2024. Dr. Klimovsky will serve as a member of the Science and Technology Committee.

BIO-TECHNE APPOINTS DR. JUDITH KLIMOVSKY TO BOARD OF DIRECTORS

MINNEAPOLIS , April 29, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities is pleased to announce a significant milestone in its commitment to providing cutting-edge solutions to its customers. Effective May 1, 2024, Bio-Techne will enter into a strategic distribution agreement with Thermo Fisher Scientific, a leading provider of laboratory products and services, in Europe.

BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH THERMO FISHER SCIENTIFIC

MINNEAPOLIS , April 26, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Novomol-Dx, a molecular diagnostics company, are pleased to announce the development of Bio-Marker Pathfinder (BMP), a first of its kind ocular biomarker kit, as a point-of-care application. Novomol-Dx is a molecular diagnostics company focused on commercializing tests for the diagnosis and treatment of ophthalmic diseases utilizing biomarkers discovered over the last decade at Narayana Nethralaya Foundation, in association with Grow Laboratories & Narayana Nethralaya, a specialty eye care hospital chain in Bangalore India.

BIO-TECHNE AND NOVOMOL-Dx ANNOUNCE POINT-OF-CARE OCULAR BIOMARKER ASSAY

Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Bio-Techne Stock (TECH)